Cellames Inc. is a leading bio-electronics company developing advanced NAMs (New Approach Methodologies) for alternative testing to animal experiments.
We create innovative solutions that allow precise analysis of electrophysiological signals from organoids and cells,
introducing a new paradigm in drug discovery and safety assessment.
Our MEA (Micro-Electrode Array) systems are designed to measure and analyze high-resolution signals from cardiomyocytes and neurons.
This makes it possible to evaluate drug-induced cardiotoxicity and neurotoxicity with accuracy and reproducibility.
In addition, our impedance systems can monitor real-time, non-destructive changes in cell proliferation, differentiation, apoptosis, toxicity, and drug responses.
This enables early detection of potential issues and provides continuous insights into cell health.
We have also developed proprietary transparent ITO (Indium Tin Oxide) disk electrode cell chips, which allow easy microscopic observation.
By combining imaging analysis with electrophysiological data, we improve both precision and reliability.
Through these advanced technologies, we are building in vitro testing methods that address the ethical concerns of animal studies and overcome challenges caused by inter-species differences.
At Cellames, we aim to contribute to human health and scientific progress by advancing NAMs-based alternative testing methods through cutting-edge bio-electronics.